Cancer Biomarkers Market
Report ID: SQMIG35H2355
Report ID: SQMIG35H2355
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35H2355 |
Region:
Global |
Published Date: November, 2025
Pages:
188
|Tables:
124
|Figures:
72
Global Cancer Biomarkers Market size was valued at USD 26.61 Billion in 2024 and is poised to grow from USD 29.75 Billion in 2025 to USD 72.61 Billion by 2033, growing at a CAGR of 11.8% during the forecast period (2026–2033).
Growing number of cancer patients around the world are projected to bolster the demand for cancer biomarkers over the coming years. High investments in oncology research and rising awareness regarding the benefits of cancer biomarkers in diagnostics and treatment of cancer are also expected to create new opportunities for cancer biomarker companies going forward. The rising adoption of gene therapies and personalized medicine to treat different cancer indications is also expected to promote the use of cancer biomarkers in the future. Advancements in biomarker research and surging preference of non-invasive and minimally invasive procedures around the world are estimated to create new opportunities for cancer biomarkers companies going forward.
On the other hand, lack of clinical validity and reproducibility, limited awareness among medical professionals, ethical concerns regarding the use of biomarkers, and stringent regulations are all expected to slow down market development in the future.
What is the Role of AI in Influencing Cancer Biomarker R&D?
Artificial Intelligence (AI) is transforming cancer biomarker discovery by analyzing vast genomic, proteomic, and clinical datasets with unmatched speed and accuracy. AI algorithms identify patterns and predict biomarker candidates that traditional methods might overlook. Deep learning models are also enhancing image-based biomarker detection through pathology and radiology data. This accelerates research timelines, improves diagnostic precision, and enables real-time patient stratification. Pharma and biotech companies increasingly integrate AI in their drug development pipelines, while startups emerge specializing in AI-driven biomarker platforms. As data availability grows, AI’s role in biomarker validation, discovery, and personalized therapy is becoming a central cancer biomarker market trend.
Market snapshot - 2026-2033
Global Market Size
USD 27.1 billion
Largest Segment
Diagnostics
Fastest Growth
Personalized Medicine
Growth Rate
12.5% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global cancer biomarkers market is segmented by profiling technology, cancer type, product, application, end user and region. Based on profiling technology, the market is segmented into omics technologies, imaging technologies. Based on cancer type, the market is segmented into non-Hodgkin's lymphoma, breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, leukemia, thyroid cancer, bladder cancer, kidney cancer, and other cancers. Based on product, the market is segmented into instruments, bioinformatics software. Based on application, the market is segmented into diagnostics, research & development, prognostics, risk assessment, personalized medicine, and other applications. Based on end user, the market is segmented into diagnostic laboratories, biopharmaceutical companies and CROs, research and academic institutes, other end users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.
For What Applications are Most Cancer Biomarkers Used?
The diagnostic applications segment is projected to account for the largest global cancer biomarkers market share . High emphasis on early diagnosis and growing investments in the development of advanced diagnostic technologies is projected to help this segment maintain its dominance. The rising use of cancer biomarkers to develop new diagnostic tests for various cancer indications will also present new opportunities for cancer biomarker providers.
On the other hand, the use of cancer biomarkers for personalized medicine applications is expected to increase at a robust CAGR across the forecast period and beyond. Rising awareness regarding the benefits of cancer biomarkers in helping create personalized treatment for patients with better chances of recovery is also estimated to help generate new business scope for market players in the future.
Which Profiling Technology Brings in the Most Revenue?
Imaging technologies segment is anticipated to spearhead the global cancer biomarkers market revenue in the future. High investments in the development of biomarker-based diagnostic imaging technologies and growing utilization of the same around the world are helping this segment generate more revenue than others. Moreover, advancements in imaging technologies and integration of artificial intelligence are further opening new business opportunities for cancer biomarker companies focusing on this segment.
Meanwhile, the use of cancer biomarkers in Omics technologies is projected to increase at a notable pace as per this cancer biomarker industry analysis. Omics technologies facilitate the discovery of novel biomarkers through the utilization of approaches such as genomics, proteomics, and metabolomics. Increasing sophistication of bioinformatics technologies and advancements in biotechnology are slated to promote the use of cancer biomarkers in this segment.
To get detailed segments analysis, Request a Free Sample Report
Why is North America the Top User of Cancer Biomarkers?
Robust investments in oncology research by public and private organizations coupled with a developed healthcare infrastructure are helping this region maintain its dominance. High healthcare expenditure and quick adoption of advanced diagnostic and treatment technologies are also estimated to help promote the demand for cancer biomarkers in North America over the coming years. Widespread use of liquid biopsies, genetic screening, and AI-enabled platforms are also creating new business scope.
Cancer Biomarkers Market in United States
High cancer incidence, presence of well-established biotech ecosystem, and strong biomarker R&D funding help this country lead cancer biomarker demand on a global level. Thermo Fisher, Guardant Health, and Roche Diagnostics are the top companies driving innovation in genomic, proteomic, and liquid biopsy platforms. Increasing reimbursement of biomarker-based tests, expansive clinical trial infrastructure, and collaborations between biotech and pharma giants help strengthen the United States’ stance as a leader in cancer biomarker innovation.
Cancer Biomarkers Market in Canada
Launch of national genomics initiatives, public healthcare support, and academic-industry collaborations are steadily driving cancer biomarker demand in Canada. The healthcare system enables centralized implementation of biomarker-guided screening and treatment, though access varies by province. Growing adoption of next generation sequencing along with companion diagnostics is also driving business scope for companies. Canada’s regulatory environment and funding support make it a strong market in this region.
Why are Cancer Biomarkers Suppliers are Investing in Asia Pacific?
The growing prevalence of different types of cancers allows Asia Pacific to emerge as the most opportune regional market for cancer biomarker companies in the world. Rising demand for better cancer diagnostics and treatments has led to high investments in oncology research in this region thereby promoting cancer biomarkers demand as well. India, China, and Japan are slated to be the leading markets for cancer biomarker providers operating in this region. Easy regulatory approvals as compared to North America and Europe are also expected to attract many cancer biomarker companies to this region in the future.
Cancer Biomarkers Market in Japan
National healthcare reforms, expanding geriatric population base, and high technology adoption in healthcare are slated to uplift cancer biomarker demand in Japan. Biomarker testing is part of the standard cancer care routine of the country. Advanced infrastructure, combined with patient awareness and strong research institutions, make Japan a leader in biomarker-guided oncology. Advancements in next generation sequencing and liquid biopsy are also creating new opportunities for cancer biomarker companies in Japan.
Cancer Biomarkers Market in South Korea
Surge in prevalence of cancer and government investment in biohealth innovations make South Korea a key market for cancer biomarker providers. High emphasis on early cancer detection by the Korean Ministry of Health is also driving up the adoption of cancer biomarker in the country. Local companies like Seegene and Geninus are focusing on multiplex diagnostics and genomic profiling innovation. Strong public-private partnerships and a tech-driven approach are accelerating biomarker integration into routine cancer diagnosis and personalized treatment strategies.
How Will Demand for Cancer Biomarkers Fare in European Countries?
Strong academic research base, launch of supportive policies, and emphasis on personalized medicine are boosting the adoption of cancer biomarker in Europe. EU programs like Horizon Europe and Europe's Beating Cancer Plan fund biomarker innovation. Collaborations between research institutions and pharma companies drive market growth, while regulatory harmonization fosters biomarker commercialization across member states, sustaining Europe’s competitive presence in oncology diagnostics.
Cancer Biomarkers Market in United Kingdom
NHS-backed screening programs, robust academic research activity, and genomic medicine initiatives are helping boost the demand for cancer biomarker in this country. The NHS integrates biomarker testing in standard cancer care pathways, particularly for lung, ovarian, and colorectal cancers. Regulatory support for companion diagnostics and focus on early detection are slated to boost clinical utilization of cancer biomarker in the United Kingdom thereby making it a key market in Europe.
Cancer Biomarkers Market in Germany
Presence of a strong biotechnology sector, research institutions, and precision medicine policies allow Germany to lead cancer biomarker demand in this region. Companies like Qiagen and BioNTech contribute to innovation in molecular diagnostics. Biomarker testing is extensively used for diagnostics of breast, lung, and colorectal cancers. Reimbursement policies and integration of companion diagnostics into treatment guidelines are also expected to ensure sustained demand for cancer biomarker in Germany over the coming years.
Cancer Biomarkers Market in France
Government-backed healthcare infrastructure and national precision oncology programs are augmenting the adoption of cancer biomarker in France. The French National Cancer Institute (INCa) supports clinical biomarker research and patient stratification. The country’s emphasis on improving universal healthcare access ensures biomarker testing availability in private as well as public hospitals. Growing demand for non-invasive diagnostics like liquid biopsy and next-generation sequencing position France as a rewarding country for cancer biomarker companies.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Cancer Biomarkers Market Drivers
Rising Incidence of Cancer
Rising Use of Liquid Biopsies
Cancer Biomarkers Market Restraints
Ethical and Privacy Concerns
Lack of Reproducibility and Clinical Viability
Request Free Customization of this report to help us to meet your business objectives.
Cancer biomarkers providers around the world are estimated to focus on research to maximize their business potential and stay competitive. Developing new therapeutics for specific cancer indications will also be a preferred strategy for new as well as leading cancer biomarkers companies. Market players can also benefit from government support to take their oncology research capabilities to the next level. Use of advanced drug discovery and development techniques will also be popular among cancer biomarker providers in the future.
The scope for innovation in biotechnology is limitless, which is why multiple startups are working in this industry. High funding availability of oncology R&D has helped cancer biomarker startups to stand out from the competition. Here’s a startup that could change the future of oncology and biomarker testing.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, growing incidence of cancer and rising investments in oncology research around the world are slated to boost the demand for cancer biomarkers over the coming years. However, lack of clinical validity and ethical concerns are projected to slow down the demand for cancer biomarkers over the coming years. North America is slated to spearhead the adoption of cancer biomarkers on the back of high healthcare expenditure and extensive oncology research activity. Use of cancer biomarkers for companion diagnostics could also provide some lucrative opportunities for cancer biomarker companies in the future. Use of artificial intelligence can also help fast-track the discovery and development of novel cancer biomarkers.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 26.61 Billion |
| Market size value in 2033 | USD 72.61 Billion |
| Growth Rate | 11.8% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Cancer Biomarkers Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Cancer Biomarkers Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Cancer Biomarkers Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Cancer Biomarkers Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
